Posts

Biogen and Denali halt Parkinson’s drug in non‑genetic Parkinson’s after mid‑stage failure

on

Remepy Reports Strong Clinical Phase IIa Results for Hybridopa, a First‑in‑Class Hybrid Drug for Parkinson’s Disease

on

AskBio's Viralgen to Supply Commercial-Scale Drug Product for REGENERATE-PD Phase II Trial in Parkinson's Disease

on

Galaxy Brain Scientific's SCAN-Targeted Technology Redefines Parkinson's Treatment Through Precision Neural Circuit Stimulation

on

Oryon Cell Therapies Emerges With $42M for Autologous Neuron Replacement Therapy in Parkinson's Disease

on

Aspen Neuroscience's Personalized Parkinson's Therapy Shows Early Promise with 12-Month Data

on

AC Immune Reports Promising Phase 2 Interim Data for Parkinson's Immunotherapy ACI-7104.056

on

Ventus Therapeutics Continues Phase 2a Trial of VENT-02 NLRP3 Inhibitor in Parkinson's Disease; No Indication of Program Halt

on

Parkinson’s Patients Prefer Medtronic’s Adaptive Brain Stimulation Over Traditional Settings, Major Study Shows

on

Novartis Takes Another Shot at Alpha-Synuclein With $2.2B Arrowhead CNS Deal

on

Roche Advances Prasinezumab Into Phase III Trials for Parkinson’s Despite Mixed Phase II Results

on

Forging the Future of Cell Therapy: Bayer and BlueRock's Unique Journey

on

Forging the Future of Cell Therapy: Bayer and BlueRock's Unique Journey

on

MeiraGTx and Hologen AI Form $430M Collaboration to Advance Parkinson's Gene Therapy

on

FDA Approves Onapgo: Breakthrough Infusion Device for Advanced Parkinson's Disease

on

Inhibikase Halts Parkinson's Drug Development After Phase II Failure, Shifts Focus to Pulmonary Arterial Hypertension

on